Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Linetta Marouf

Physician Assistant, Medical Rochester Hills, MI Physician Assistant

NPI 1619046513 CMS profile 10631451

1555 South Blvd E Ste 320, Rochester Hills, MI 48307

Open in the dashboard

General payments

$6,263

292 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Linetta Marouf of Rochester Hills, MI is reported in the CMS Open Payments database as having received $6,263 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,520 64
2024 General $1,745 80
2023 General $1,722 75
2022 General $621 32
2021 General $655 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linetta Marouf
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Linetta Marouf were reported at $1,520. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Linetta Marouf Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $655 $156 $41–$563 $132
2022 $621 $185 $55–$649 $149
2023 $1,722 $199 $58–$717 $160
2024 $1,745 $206 $62–$740 $164
2025 $1,520 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,890 87 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $876 43 payments
  3. Ardelyx, Inc. $445 24 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $416 22 payments
  5. Janssen Biotech, Inc. $397 17 payments
  6. Pfizer Inc. $346 16 payments
  7. Gilead Sciences, Inc. $257 9 payments
  8. Genzyme Corporation $226 9 payments
  9. Ironwood Pharmaceuticals, Inc $226 9 payments
  10. Regeneron Healthcare Solutions, Inc. $207 8 payments
  11. Other $977 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,179 291 payments
  2. Education $84 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $759 35 payments
  2. XIFAXAN $645 26 payments
  3. SKYRIZI Immunology $587 28 payments
  4. LINZESS $506 24 payments
  5. IBSRELA $445 24 payments
  6. TRULANCE $380 20 payments
  7. CREON $364 20 payments
  8. SKYRIZI Immunology $355 12 payments
  9. XELJANZ $317 15 payments
  10. STELARA $304 15 payments
  11. Other $3,349 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,560

Median for Physician Assistant: 241

Drug cost

$180,191

Median for Physician Assistant: $4,110

Branded share of claims

15.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 163 $135,857
Dexlansoprazole Dr Dexlansoprazole Brand 16 $7,893
Mesalamine Er Mesalamine Brand 30 $6,703
Pantoprazole Sodium Generic 349 $5,352
Mesalamine Generic 11 $4,905
Sucralfate Generic 108 $4,205
Famotidine Generic 262 $3,191
Omeprazole Generic 241 $2,912
Lubiprostone Generic 12 $2,364
Hydrocortisone Generic 99 $1,819

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
  • AbbVie, Inc. $158
  • Ironwood Pharmaceuticals, Inc $81
$238 163 —
IBSRELA
  • Ardelyx, Inc. $193
$193 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $100
  • GENZYME CORPORATION $78
$178 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $167
$167 — —
RINVOQ
  • AbbVie, Inc. $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record